TY - JOUR
T1 - Carbohydrate-based adjuvants
AU - Garcia-Vello, Pilar
AU - Speciale, Immacolata
AU - Chiodo, Fabrizio
AU - Molinaro, Antonio
AU - De Castro, Cristina
N1 - Funding Information:
P.G-V. fellowship is supported by MSCA-ITN-ETN ‘Train2Target’ project granted from the European Union's Horizon 2020 framework program for research and innovation (Project #721484); A.M. and C.D.C. acknowledge MSCA-ITN-ETN ‘Train2Target’ project granted from the European Union's Horizon 2020 framework program for research and innovation (Project #721484); F.C. acknowledges COST Action CA18103, ‘Innovation with Glycans: new frontiers from synthesis to new biological targets’; A.M. also acknowledges COST action CA16231 ‘ENOVA, European Network of Vaccine Adjuvants’.
Publisher Copyright:
© 2020 The Author(s)
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2020/12
Y1 - 2020/12
N2 - Carbohydrate adjuvants are safe and biocompatible compounds usable as sustained delivery systems and stimulants of ongoing humoral and cellular immune responses, being especially suitable for the development of vaccines against intracellular pathogens where alum is useless. The development of new adjuvants is difficult and expensive, however, in the last two years, seven new carbohydrate-based adjuvants have been patented, also there are twelve ongoing clinical trials of vaccines that contain carbohydrate-based adjuvants, as well as numerous publications on their mechanism of action and safety. More research is necessary to improve the existent adjuvants and develop innovative ones.
AB - Carbohydrate adjuvants are safe and biocompatible compounds usable as sustained delivery systems and stimulants of ongoing humoral and cellular immune responses, being especially suitable for the development of vaccines against intracellular pathogens where alum is useless. The development of new adjuvants is difficult and expensive, however, in the last two years, seven new carbohydrate-based adjuvants have been patented, also there are twelve ongoing clinical trials of vaccines that contain carbohydrate-based adjuvants, as well as numerous publications on their mechanism of action and safety. More research is necessary to improve the existent adjuvants and develop innovative ones.
UR - http://www.scopus.com/inward/record.url?scp=85092257772&partnerID=8YFLogxK
U2 - 10.1016/j.ddtec.2020.09.005
DO - 10.1016/j.ddtec.2020.09.005
M3 - Review article
C2 - 33388128
AN - SCOPUS:85092257772
VL - 35-36
SP - 57
EP - 68
JO - Drug Discovery Today: Technologies
JF - Drug Discovery Today: Technologies
SN - 1740-6749
ER -